120 likes | 214 Views
Gene expression profiles relate to gene fusion type and metastasis in synovial sarcoma. J. Fernebro, P. Francis , P. Edén, Å. Borg, I. Panagopoulos, F. Mertens, J. Vallon-Christersson, M. Åkerman, N. Mandahl, M. Nilbert
E N D
Gene expression profiles relate to gene fusion type and metastasis in synovial sarcoma J. Fernebro, P. Francis, P. Edén, Å. Borg, I. Panagopoulos, F. Mertens, J. Vallon-Christersson, M. Åkerman, N. Mandahl, M. Nilbert Departments of Oncology, Theoretical Physics, Clinical Genetics, and Pathology Lund University, Sweden Princy.Francis@onk.lu.se
Aims • Groups of genes discriminating the monophasic from biphasic • have been previously identified • (Allander et al., 2002; Nagayama et al., 2002) • Do gene expression profiles in synovial sarcoma correlate with: • Histopathology • Cytogenetics • Gene fusion type • Metastatic potential
Material SS18 SSX 23 synovial sarcoma specimens from 21 patients mean age 46, 12 males, 16 primary tumors, 3 local recurrences, 4 metastases • Histopathologymonophasic (17)vs biphasic (4) • Cytogenetics t(X;18) (4)vs complex karyotype (12) • Gene fusion type SS18/SSX1 (12) vsSS18/SSX2 (7) • Metastatic potential metastasis (13)vs metastsis-free (5)
Methods Tumour RNA Reference RNA Labelled cDNA Hybridize to microarray slide 18-20 hrs incubation at 42oC Scan Image and Data Analysis Process Image • cDNA microarray, 27648 IMAGE clones • distinct reporters • 17517 unique UniGene clusters • Hierarchical clustering • based on ~5800 genes • - Unsupervised • - Supervised • Golub scores, random permutation tests
Supervised clustering • Metastasis • No • Yes • Gene fusion type • Type 1 • Type 2 • Expression profiles did not relate to histopathology or karyotype • Significant discriminators for gene fusion type and metastatic potential
Discriminating genes Gene fusion type Metastatic potential Up SS18/SSX1 • - TCF7 - LEF1 • - RTP801 - CKB • - NOTCH2 - Metallothioneins Up metastasis • - TYMS - TOP2A • - PTTG1 - IGFBP2 • - BUB1 - COL18A1 Up SS18/SSX2 • - BENE - MN1 • - NEDD4 - FRAG1 • MSX2 - TIEG Up without metastasis • - ProSAPiP1 - TNNT1 • - ICAM1 - DDX21 • - FRAG1 - TCF8 • Cell proliferation • Cell cycle progression • Transcriptional regulation • Transcription factors • Signalling molecules • Multiple metallothioneins
Discriminating genes Gene fusion type Metastatic potential Up SS18/SSX1 • - TCF7 - LEF1 • - RTP801 - CKB • - NOTCH2 - Metallothioneins Up metastasis • - TYMS - TOP2A • - PTTG1 - IGFBP2 • - BUB1 - COL18A1 Up SS18/SSX2 • - BENE - MN1 • - NEDD4 - FRAG1 • MSX2 - TIEG Up without metastasis • - ProSAPiP1 - TNNT1 • - ICAM1 - DDX21 • - FRAG1 - TCF8 Common discriminators • BSG - FRAG1 • NOTCH2 - RGS2 • - TCF7 - TCF8 • 45 from top 200 common to both lists • Up in metastasis also up in SS18/SSX1
Discriminating genes Gene fusion type Metastatic potential Up SS18/SSX1 • - TCF7 - LEF1 • - RTP801 - CKB • - NOTCH2 - Metallothioneins Up metastasis • - TYMS - TOP2A • - PTTG1 - IGFBP2 • - BUB1 - COL18A1 Up SS18/SSX2 • - BENE - MN1 • - NEDD4 - FRAG1 • MSX2 - TIEG Up without metastasis • - ProSAPiP1 - TNNT1 • - ICAM1 - DDX21 • - FRAG1 - TCF8 Targets for chemotherapeutic drugs
Discriminating genes Gene fusion type Metastatic potential Up SS18/SSX1 • - TCF7 - LEF1 • - RTP801 - CKB • - NOTCH2 - Metallothioneins Up metastasis • - TYMS - TOP2A • - PTTG1 - IGFBP2 • - BUB1 - COL18A1 Up SS18/SSX2 • - BENE - MN1 • - NEDD4 - FRAG1 • MSX2 - TIEG Up without metastasis • - ProSAPiP1 - TNNT1 • - ICAM1 - DDX21 • - FRAG1 - TCF8 Previously reported in synovial sarcoma
Discriminating genes Gene fusion type Metastatic potential Up SS18/SSX1 • - TCF7 - LEF1 • - RTP801 - CKB • - NOTCH2 - Metallothioneins Up metastasis • - TYMS - TOP2A • - PTTG1 - IGFBP2 • - BUB1 - COL18A1 Up SS18/SSX2 • - BENE - MN1 • - NEDD4 - FRAG1 • MSX2 - TIEG Up without metastasis • - ProSAPiP1 - TNNT1 • - ICAM1 - DDX21 • - FRAG1 - TCF8 Previously reported in metastasizing tumors
Conclusions • Differentially expressed genes relative to gene fusion type and metastatic potential in synovial sarcoma • Signaling molecules, transcription factors and metallothioneins among the fusion type discriminating genes • Known targets for chemotherapy (TYMS and TOP2A) upregulated in metastasizing tumors